Trial Profile
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2019
Price :
$35
*
At a glance
- Drugs Pegcantratinib (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Creabilis SA
- 14 May 2019 Primary endpoint has been met. (Efficacy of CT327 ointment (0.05%) compared with placebo ointment and the Investigator's Global Assessment (IGA) 2-grade composite, comprising a 2-grade improvement from baseline.) according to a Sienna Biopharmaceuticals media release.
- 21 Mar 2014 Results will be presented at the 72nd Annual Meeting of the American Academy of Dermatology (AAD) according to a Creabilis SA media release.
- 10 May 2013 Top-line results reported in a Creabilis media release.